DrugPatentWatch Database Preview
Patent: 8,617,840
» See Plans and Pricing
Summary for Patent: 8,617,840
| Title: | Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes |
| Abstract: | Lysis/resealing process for preparing erythrocytes which contain an active ingredient (e.g. aspariginase or inositol hexaphosphate), the process comprising the following steps: (1) placing a globular concentrate in suspension in an isotonic solution having a haematocrit level which is equal to or greater than 65%, with refrigeration at from +1 to +8.degree. C., (2) measuring the osmotic fragility based on a sample of erythrocytes from that same globular concentrate, preferably on a sample of the suspension obtained in step (1), (3) lysis and internalization procedure of the active ingredient, inside the same chamber, at a temperature which is constantly maintained at from +1 to +8.degree. C., comprising allowing the erythrocyte suspension having a haematocrit level which is equal to or greater than 65% and a hypotonic lysis solution which is refrigerated at from +1 to +8.degree. C. to circulate in a dialysis cartridge; the lysis parameters being adjusted in accordance with the osmotic fragility previously measured; and (4) resealing procedure carried out in a second chamber at a temperature of from +30 to +40.degree. C. by means of a hypertonic solution. |
| Inventor(s): | Godfrin; Yann (Lyons, FR) |
| Assignee: | Erytech Pharma (Lyons, FR) |
| Application Number: | 11/573,093 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,617,840
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | ELSPAR | asparaginase | VIAL | 101063 | 001 | 1978-01-10 | Start Trial | Erytech Pharma (Lyons, FR) | 2024-08-05 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,617,840
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006016247 | Start Trial |
| United States of America | 10273444 | Start Trial |
| United States of America | 2008261262 | Start Trial |
| United States of America | 2014154797 | Start Trial |
| Slovenia | 1773452 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
